ANDREW CALDWELL: Open Payments
NPI 1679942916 · TOOELE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$565 in 29 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $591 · 2025 $565
Food & beverage: $565
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $211 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $71 |
| Novo Nordisk Inc | 4 | $63 |
| Medtronic, Inc. | 2 | $45 |
| Indivior Inc. | 2 | $43 |
| Lundbeck LLC | 1 | $29 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
Products named: VRAYLAR, CAPLYTA, Wegovy, SUBLOCADE, REXULTI, JOURNAVX, VERQUVO, INTELLIS ADAPTIVESTIM.
Industry payments across UT — which companies pay providers there.
